00917nam--2200337---450-99000206568020331620090401143220.0000206568USA01000206568(ALEPH)000206568USA0100020656820041008d1966----km-y0itay0103----baengUK||||||||001yyMalthus and his workJames BonarLondonCassa & Co.1966X, 440 p.ill.24 cm20012001001-------2001BONAR,James119745ITsalbcISBD990002065680203316330 BON 1 (ISE VII 6)12298 E.C.ISE VII00148632BKECOSIAVPROV1020041008USA011702RSIAV59020090401USA011432Malthus and his work476265UNISA03881nam 22005175 450 991098461220332120200424112023.09780520309807052030980410.1525/9780520309807(CKB)5280000000211703(DE-B1597)542867(OCoLC)1149442015(DE-B1597)9780520309807(MiAaPQ)EBC30495384(Au-PeEL)EBL30495384(OCoLC)1377819876(EXLCZ)99528000000021170320200424h19811981 fg engur|||||||||||txtrdacontentcrdamediacrrdacarrierPills and the Public Purse The Routes to National Drug Insurance /Milton Silverman, Mia Lydecker, Philip R. LeeReprint 2019Berkeley, CA : University of California Press, [1981]©19811 online resource (256 p.) 4 tables9780520304710 0520304713 Frontmatter -- Contents -- List of Tables -- Foreword -- Preface -- A Note About the Authors -- PART I. THE PILLS -- PART II. PATIENTS, PHYSICIANS, AND PHARMACISTS -- PART III. COST-CONTAINMENT: LOW COST OR HIGH QUALITY-OR BOTH? -- PART IV. THE PUBLIC PURSE -- Appendix -- Key to Abbreviations Used in the References -- References -- IndexIf national health insurance becomes a reality, what options should be considered for the coverage of prescription drugs? The authors--whose Pills, Profits, and Politics has had a dramatic effect on physicians, pharmacists, patients, and the drug industry as well as on federal and state legislators--insist that the major objective must be the best possible health care. But holding down costs to patients and taxpayers must also be a goal.   To complicate matters further, the advantage of each likely option--including price controls, the use of formularies, drug utilization review, patient cost-sharing, and the use of low-cost, generic-name products--is offset by a disadvantage, even a danger. If drug prices are slashed too much, the industry will lose many of its incentives to develop better drugs for the future.   Particular attention is focused on the so-called drug lag--the lengthy delays in licensing of new drugs, even after they have been used with apparently good results in other countries. Pills and the Public Purse also addresses the seldom-appreciated fact that investing tax dollars in needed drugs may save taxpayers in the long run by minimizing unnecessary physician visits and hospitalization.   Pills and the Public Purse challenges Congress and such agencies as the Food and Drug Administration and the Health Care Financing Administration to enact policies that put the interests of the public before those of government, industry, physicians, and pharmacists.  This title is part of UC Press's Voices Revived program, which commemorates University of California Press's mission to seek out and cultivate the brightest minds and give them voice, reach, and impact. Drawing on a backlist dating to 1893, Voices Revived makes high-quality, peer-reviewed scholarship accessible once again using print-on-demand technology. This title wasoriginally published in 1981.NON-CLASSIFIABLEbisacshNON-CLASSIFIABLE.368.4/2Silverman Milton, authttp://id.loc.gov/vocabulary/relators/aut1793815Lee Philip R., authttp://id.loc.gov/vocabulary/relators/autLydecker Mia, authttp://id.loc.gov/vocabulary/relators/autDE-B1597DE-B1597BOOK9910984612203321Pills and the Public Purse4333825UNINA01027nam 22003493 450 991014617120332120250414123126.097888667719448866771945(CKB)1000000000279993(ItFiC)it 05902990(EXLCZ)99100000000027999320060828d2005 uy 0itaur|||||||||||Globalizzazione e glocalizzazione /Zygmunt Bauman ; saggi scelti a cura di Peter BeilharzRoma Armando2005 (2004 printing)415 pModernità e societàOrig. title: The Bauman reader.Transl. by Edmondo Coccia.Contains general index (p. 391-415).9788883585432 8883585437 303Bauman Zygmunt1925-124491ItFiCItFiCBOOK9910146171203321Globalizzazione e glocalizzazione739184UNINA